Verrica Pharma Files Q1 2025 10-Q, Details Torii Deal & Financing
Ticker: VRCA · Form: 10-Q · Filed: May 13, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financing, agreements
TL;DR
Verrica's Q1 10-Q is out. Torii deal updates, debt financing, and Ycanth progress are key. **Check it out.**
AI Summary
Verrica Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including references to agreements with Torii Pharmaceutical Company Limited and financing activities such as a debt financing and a loan facility. The company is focused on its products like Ycanth.
Why It Matters
This filing provides insight into Verrica's financial health and strategic partnerships, which could impact its stock performance and future product development.
Risk Assessment
Risk Level: medium — The company's financial disclosures and ongoing agreements suggest potential risks and opportunities that could affect its valuation.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the financial period covered by the report.)
- 2025-05-13 — Filing Date (Shows when the report was officially submitted to the SEC.)
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Filer of the 10-Q
- Torii Pharmaceutical Company Limited (company) — Partner in an agreement
- Ycanth (product) — Mentioned product
- 20250331 (date) — End of reporting period
- 20250513 (date) — Filing date
FAQ
What is the current status of the agreement with Torii Pharmaceutical Company Limited as detailed in this filing?
The filing references 'vrca:ToriiAgreementMember' and 'vrca:ToriiAmendmentMember' in relation to Torii Pharmaceutical Company Limited, indicating ongoing or amended contractual relationships.
What specific financing activities are mentioned in the Q1 2025 10-Q?
The filing mentions 'vrca:DebtFinancingMember' and 'vrca:LoanFacilityMember', suggesting debt-related financial activities during the reporting period.
Are there any updates regarding the product Ycanth?
Yes, 'vrca:YcanthMember' is referenced in the filing, indicating its continued relevance to the company's operations.
What is the fiscal year end for Verrica Pharmaceuticals Inc.?
The fiscal year end for Verrica Pharmaceuticals Inc. is December 31 (1231).
What is the primary business of Verrica Pharmaceuticals Inc. according to the SIC code?
According to the Standard Industrial Classification code [2834], Verrica Pharmaceuticals Inc. is involved in Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Verrica Pharmaceuticals Inc. (VRCA).